Get access

A novel therapeutic drug for colon cancer: EpCAM scFv-truncated protamine (tp)-siRNA

Authors

  • Huiwen Hao,

    1. Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, College of Life Science, Northwest University, Xi'an, China
    Search for more papers by this author
  • Yansen Zhen,

    1. Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, College of Life Science, Northwest University, Xi'an, China
    Search for more papers by this author
  • Zaicun Wang,

    1. Department of Biomedical Engineering, Peking University, Beijing, China
    Search for more papers by this author
  • Fulin Chen,

    1. Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, College of Life Science, Northwest University, Xi'an, China
    Search for more papers by this author
  • Xin Xie

    Corresponding author
    1. Department of Translational Medicine, Institute of Integrated Medical Information, Xi'an, China
    • Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, College of Life Science, Northwest University, Xi'an, China
    Search for more papers by this author

  • Huiwen Hao and Yansen Zhen have contributed equally to this hypothesis.

Corresponding author: e-mail: xiexin@nwu.edu.cn

Abstract

Colon cancer is a type of malignant tumor that causes considerable mortality worldwide. Epithelial cellular adhesion molecule (EpCAM), a tumor-associated antigen of colon tumors, is a target for colon cancer therapy. EpCAM-specific monoclonal antibodies (mAbs) have been applied in human colon cancer since the 1990s; however, the therapeutic effects are limited. EpCAM activates nuclear signaling pathways by releasing its intracellular domain (EpICD). The released EpICD stimulates the Wnt/β-catenin signaling pathway, which is also strongly associated with tumorigenesis. EpCAM is also a target gene of the Wnt/β-catenin signaling pathway. EpCAM and the Wnt/β-catenin signaling pathway form a functional interaction cycle in colon cancer. Thus, we propose a new therapeutic drug for colon cancer: an EpCAM single-chain fragment variable antibody (scFv)-truncated protamine-siRNA. EpCAM scFv can recognize and bind colon cancer cells through its EpCAM antigen activity. Furthermore, the specific siRNA transferred into colon cancer cells specifically inhibits Wnt/β-catenin signal transmission. Therefore, this new drug may efficiently interrupt the functional cycle between EpCAM and Wnt/β-catenin signaling and be an effective therapeutic strategy for colon cancer.

Get access to the full text of this article

Ancillary